Collagen-specific peptide conjugated HDL nanoparticles as MRI contrast agent to evaluate compositional changes in atherosclerotic plaque regression.
about
Nanoparticles for Cardiovascular Imaging and Therapeutic Delivery, Part 1: Compositions and FeaturesMolecular imaging of atherosclerosis with nanoparticle-based fluorinated MRI contrast agentsNature-inspired nanoformulations for contrast-enhanced in vivo MR imaging of macrophages.In vivo MR and Fluorescence Dual-modality Imaging of Atherosclerosis Characteristics in Mice Using Profilin-1 Targeted Magnetic Nanoparticles.Recent Advances in Targeted, Self-Assembling Nanoparticles to Address Vascular Damage Due to Atherosclerosis.EMMPRIN-Targeted Magnetic Nanoparticles for In Vivo Visualization and Regression of Acute Myocardial Infarction.Targeting and therapeutic peptides in nanomedicine for atherosclerosis.Molecular MRI of atherosclerosis.Visualizing the atherosclerotic plaque: a chemical perspective.Targeting collagen for diagnostic imaging and therapeutic delivery.Molecular Cardiovascular Magnetic Resonance: Current Status and Future Prospects.Lipoproteins and lipoprotein mimetics for imaging and drug delivery.Molecular MRI of atherosclerotic plaque progression in an ApoE(-/-) mouse model with a CLT1 peptide targeted macrocyclic Gd(III) chelate.Determining collagen distribution in articular cartilage using contrast-enhanced micro-computed tomography.Magnetic Resonance Imaging of Atherosclerotic Plaque at Clinically Relevant Field Strengths (1T) by Targeting the Integrin α4β1.The Multifaceted Uses and Therapeutic Advantages of Nanoparticles for Atherosclerosis Research.Uptake of citrate-coated iron oxide nanoparticles into atherosclerotic lesions in mice occurs via accelerated transcytosis through plaque endothelial cells
P2860
Q26798426-16E5F41D-7652-49BF-8BB4-503551C0B49BQ27027613-993E4215-B58B-4205-8AE6-7881A3FED9E3Q34339353-36D13797-A2F9-4FF1-B8E2-026E3C36DCAAQ36510880-A5C9BA0E-D85D-451A-A38F-D15520146F18Q36598388-B07C50E0-9DD5-425B-AAE5-493DB5848F42Q36644344-78D73725-DD87-47E1-9CD9-BBE03B2FCBC7Q36913594-72C44DB9-1549-4BE3-8CDF-7C1B95CB3DE4Q38162728-88EA569B-8131-4542-AE33-C45BD6BA687BQ38187881-32E0F382-2B27-43DA-9C34-D03C5C2337A7Q38698660-3DB59BA1-D614-4988-ACA9-B3C07AE76D88Q38796404-82F41192-FBDC-4864-8F93-AE046330077DQ38822339-79CEAE1D-73AA-49A2-AC11-D7796EB97B18Q41847179-A3067B63-FB65-4D64-863C-2AEA8BED04F1Q42582864-02A990CD-6061-4DEC-9BCC-A7DADE5C61DCQ50355298-E3A762A4-6AB5-4EF0-9778-D3DF4D102297Q54402965-68EF03D0-E5F2-42FE-AE1F-62BC0522DCE2Q57603322-5D108155-0FDB-4DC6-B000-0E2051BDA60A
P2860
Collagen-specific peptide conjugated HDL nanoparticles as MRI contrast agent to evaluate compositional changes in atherosclerotic plaque regression.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Collagen-specific peptide conj ...... rosclerotic plaque regression.
@en
type
label
Collagen-specific peptide conj ...... rosclerotic plaque regression.
@en
prefLabel
Collagen-specific peptide conj ...... rosclerotic plaque regression.
@en
P2093
P2860
P50
P1476
Collagen-specific peptide conj ...... erosclerotic plaque regression
@en
P2093
Ahmed Klink
Beatriz Herranz
Jonathan E Feig
Yuliya Vengrenyuk
Zahi A Fayad
P2860
P304
P356
10.1016/J.JCMG.2012.06.016
P577
2013-02-20T00:00:00Z